Home > Courses > ACTHIV 2018 - Real World Management of HCV in HIV: Approach to Initial Therapy with Focus on DAAs

ACTHIV 2018 - Real World Management of HCV in HIV: Approach to Initial Therapy with Focus on DAAs

ACTHIV 2018 - Real  World  Management  of  HCV  in  HIV:  Approach  to  Initial  Therapy  with
Sorry, this learning module is not available for mobile devices.
Original Release Date: 4/6/2018
Review Date: 9/15/2018

The enduring material is jointly provided by Beaumont Health, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).

The 12th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 5-7, 2018 in Chicago, IL. The Conference was supported by the Clinical Education Initiative, New York State Department of Health, AIDS Institute, and Midwest AIDS Education & Training Center Program. The conference and this web archive were supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; and Merck & Co. The web archive is also supported by an educational grant from ViiV Healthcare.


This module is no longer available for credit.

Kristen Marks, MD, MS, Assistant Professor of Medicine and ID Fellowship Program Director, Weill Cornell Medical College

Estimated time to complete: 45 minutes

Members of the HIV care team who are frontline providers of care to persons at risk of or with HIV infection, including physicians (both specialists and primary care/family medicine), nurse practitioners, physician assistants, nurses. Physician assistants, pharmacists, case managers and other healthcare professionals.

Learning Objectives
As a result of participating in this activity, participants should be better able to:

  • Describe regimens recommended for initial treatment of HCV infection in HIV-infected persons
  • Recognize when to do testing for HCV resistance
  • Identify the advantages and limitations of newly approved HCV treatment regimens



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Beaumont Health, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV). Beaumont Health is accredited by the ACCME to provide continuing medical education for physicians.

Beaumont Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Nurse Practitioners:

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

American Academy of CME, Inc. designates this educational activity for 0.75 contact hours (0.7 pharmacotherapeutic contact hours).

Physician Assistants:

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

All other participants will receive a certificate of participation.

There is no fee to participate in this activity.


In order to obtain your certificate of credit, you must:

  • read the CME/CE information and review the full content of the activity
  • achieve a passing grade on the post-test (75% or greater), and
  • complete the evaluation.

Your certificate for the activity will be made available immediately to print online.


According to the disclosure policy of Academy and Beaumont, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures will be made known to the participants prior to the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, Beaumont, ACTHIV or the American Nurses Credentialing Council's Commission on Accreditation. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Off-Label Usage Disclosure

This activity contains off-label discussion.

Faculty Disclosure

Kristen M. Marks, MD, MS, has has indicated the following relevant financial relationships: Grant Recipient/Research Support: Bristol-Myers Squibb, Gilead Sciences, Merck & Co.

Planner Disclosures

The following planners have indicated they have no relevant financial relationships to disclose: Erika Aaron, MSN, CRNP; Julie Barroso, PhD, ANP, RN, FAAN; John T. Brooks, MD; Gina Brown, MD; Maggie Chartier, PhD, MPH; Sherrillyn Crooks, PA-C; Monica Gandhi, MD, MPH; John JD Juchniewicz, MCIS, CHCP; H. Nina Kim, MD, MSc; Natalie Kirkwood, RN, BSN, JD; Harry Lampiris, MD; Sharon Lee, MD; Bill G. Kapogiannis, MD; Edward Moylan, RP; Asa E. Radix, MD, MPH; Dianne Rausch, PhD; Cheryl Smith, MD; Brooke J. Taylor, MPH, CHCP; Ronald Dean Wilcox, MD; Barbara A. Young, MSW, LCSE, LCADC, SAC.

The following planners have indicated they have relevant financial relationships to disclose:

Judith A. Aberg, MD: Advisory Board: Janssen Therapeutics, Merck & Co., ViiV Healthcare; Grant/Research Support: Bristol-Meyers Squibb, Gilead Sciences, GlaxoSmithKline, Shionogi
Roger Bedimo, MD: Advisory Board: Merck & Co, Theratechnologies, ViiV Healthcare; Grant/Research Support: Bristol-Myers Squibb, Merck & Co.
Carlos del Rio, MD: Consultant: ViiV Healthcare; Board Member: HIVMA, IAS-USA
Donna Futterman, MD: Grant/Research Support: Gilead Sciences
Rajesh Gandhi, MD: Consultant: EMD Serono, Theratechnologies; Educational Grant Recipient /Research Support: Gilead Sciences, Merck & Co., ViiV Healthcare
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board: Gilead Sciences, Merck & Co., ViiV Healthcare; Chair, Board of Directors: American Academy of HIV Medicine; Promotional Speaker’s Bureaus: Gilead Sciences, Merck & Co., ViiV Healthcare.
Vincent Lo Re, MD, MSCE: Grant/Research Support: AstraZeneca
Tonia Poteat, PhD, MPH, PA-C: Research Support: ViiV Healthcare
Renslow Sherer, MD: Advisory Board: Gilead Sciences
William R. Short, MD, MPH: Advisory Board: Gilead Sciences; Promotional Speakers Bureau: Janssen Therapeutics
Pablo Tebas, MD: Consultant: Gilead Sciences, Merck & Co., ViiV Healthcare
Melanie Thompson, MD: Grant Recipient/Research Support: Bristol-Myers Squibb, CytoDyn, Gilead Sciences, GlaxoSmithKline, Merck Sharp Dohme, Roche Molecular Systems, Taimed, ViiV Healthcare
Carole Treston, RN, MPH, ACRN, FAAN: Community Advisory Board: Gilead Sciences
Andrea Weddle, MSW: Speaker (public policy event): ViiV Healthcare (GSK)
Susan Ellen Weiss, FNP: Advisory Board: Gilead Sciences; Consultant: Gilead Sciences, Janssen Pharmaceuticals; Promotional Speaker’s Bureau: Gilead Sciences, Janssen Therapeutics

Privacy Policy
For more information about Beaumont's privacy policy, please access https://www.beaumont.org/patients-families/patients-rights-privacy/privacy
For more information about Academy privacy policy, please access http://www.academycme.org/privacy.htm

For CME information or credit details, contact: cme@beaumont.edu

For CNE information or credit details, contact: CEServices@academycme.org

Hardware/Software Requirements To access this activity hardware and software requirements are noted below.

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later

Copyright 2018. American Academy of CME, Inc., Beaumont Health, and American Conference for the Treatment of HIV.

Bibliographic Sources:

  • Kristen Marks, MD
    Assistant Professor of Medicine
    Weill Cornell Medical College
Presenter Bio
Kristen Marks, MD
Dr. Marks is Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at New York Presbyterian Hospital. She received her medical degree from Columbia University, College of Physicians and Surgeons, and is board certified in Internal Medicine and Infectious Diseases. Dr. Marks completed Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital, where she focused her clinical training and research on HIV and hepatitis virus infections. She also completed Weill Cornell's Master's Degree in Clinical Investigation. Dr. Marks’ research focuses on improving treatment outcomes in patients with HIV and hepatitis virus co-infections and includes studies of acute HCV as well as new treatment strategies for chronic HCV. She was the vice chair of an AIDS Clinical Trials Group (ACTG) multi-center study, currently serves on 3 other ACTG hepatitis protocol teams, and is a member of the ACTG Hepatitis Transformative Science Group. She is co-investigator in the Cornell HIV/AIDS Clinical Trials Unit and Center for Study of Hepatitis C, where she is the site PI for 5 treatment studies and 2 other protocols related to HCV. She also sits on IDSA, AASLD, and IAS-USA’s joint guidelines panel for “Recommendations for testing, managing and treating hepatitis C”.